A clinical study to investigate the infusion of an amino acids solution to protect the kidneys during radiotheranostics for patients diagnosed with metastatic prostate cancer.
Phase 2
- Conditions
- Chronic renal injuriesMetastatic castrate-resistant prostate cancerCancer - KidneyCancer - Prostate
- Registration Number
- ACTRN12624000695505
- Lead Sponsor
- Fiona Stanley Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
1.Male patients aged >18 yrs
2.History of histologically confirmed prostate cancer
3.Metastatic patients who are considered for ongoing treatment with 177Lu–PSMA-617
4.Ability to understand and the willingness to sign a written informed consent
Exclusion Criteria
1.Life expectancy less than 6 months
2.Unable to give informed consent
3.Unable to comply with required scanning schedule.
4.Other malignant tumors that are likely to express PSMA, such as salivary gland, renal or hepatocellular carcinoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method